XNCR: רווח נקי למניה (EPS TTM) Xencor Corp

Xencor, Inc. offsets its R&D costs through licensing fees from partners. The trailing 12-month EPS reflects profitability trends, while -1.60 indicates the current level of the metric. Geopolitical tensions and sanctions hinder the export of oncology drugs, complicating global trials. The business model relies on outsourcing production and testing via CRO/CMO to reduce capital expenditures.

This indicator measures the real equity value of the business by dividing the aggregate net income over the last four quarters by the total number of shares to determine the actual earnings per share. By analyzing the rolling annual earnings per share, an investor can assess the monetization efficiency of the Xencor, Inc. (XNCR) antibody platform within the immuno-oncology segment, which confirms the fundamental stability of the asset.